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The value of incorporating immunologic
data for the toxicologic assessment of drugs,
chemicals, biologics, and medical devices for
human risk assessment has been increasingly
accepted. In this respect, guidelines exist
within many programs and centers at the
U.S. Environmental Protection Agency
(EPA) and the U.S. Food and Drug
Administration, as well as the Organization
for Economic Cooperation and Development,
the Committee for Proprietary Medicinal
Products and the Ministry of Health and
Welfare in Europe and Japan, for immuno-
toxicity testing in adult rodents. Since the
1970s, experimental animal studies and, to a
lesser extent, human studies have been pub-
lished describing immunologic effects in
neonates putatively exposed to toxic agents
during the prenatal or early postnatal period
(reviewed in Barnett 1996; Dietert et al. 2000;
Holladay and Smialowicz 2000). A recent lit-
erature search using the key words “immuno-
suppression” and “neonate” identified more
than 1,000 reports published during the last
decade. Although the majority of these studies
described agents used for immunosuppressive
therapies and chemotherapy, many described
developmental immunotoxicity associated with
exposure to environmental or occupational
agents. Although only a few of this latter group
represented studies in human populations and
many suffered from design flaws (e.g., small
populations), taken together they provided suf-
ficient warning to raise concern regarding the
potential health effects associated with expo-
sures in infants and children. Of particular
concern was that immunotoxicity often
appeared more severe and/or persistent when
the exposure occurred perinatally when com-
pared with exposure in adult animals. These
concerns were highlighted in a 1993 report
from the National Research Council titled
Pesticides in the Diets of Infants and Children
(National Research Council 1993), in which
the immune, reproductive, and nervous sys-
tems were identified as potential targets for
pesticide exposure. Although considerable
attention has focused on the identification,
characterization, and standardization of meth-
ods for developmental neurotoxicity and
reproductive toxicity (e.g., Garman et al.
2001; Levine and Butcher 1990; Schwetz and
Tyl 1987) only limited discussions on devel-
opmental immunotoxicity have occurred
(Dietert et al. 2000; Holsapple 2002). The
present workshop extends these earlier discus-
sions by establishing a consensus on the most
appropriate experimental designs and methods
to identify and characterize developmental
immunotoxicity in experimental animals
given our current knowledge.
Background
Because the committee had neither the oppor-
tunity nor the intent to conduct a thorough
literature review, a complete list of agents
reported to cause developmental immunotoxi-
city in humans and animals is not provided in
this report; the reader is referred to earlier
reviews on this subject (Barnett 1996;
Holladay and Luster 1994; Holladay and
Smialowicz 2000). The work group instead
provided examples of agents believed to repre-
sent developmental immunotoxicants based
on confirmed, peer-reviewed experimental
studies and/or human reports (Table 1). Few,
if any, of these agents can be considered
uniquely immunotoxic to the neonate because
most also demonstrate immunotoxicity after
adult exposure. However, for the most part,
the agents listed produce either more severe or
persistent effects after perinatal exposure than
those observed after adult exposure, which
appears consistent with our current under-
standing of the immune system. For example,
damage to the thymus during lymphocyte
selection, which occurs primarily during the
perinatal period, would have a more profound
effect than postmaturational thymic damage.
Similarly, destruction of neonatally abundant
pluripotent stem cells would likely have a
more pervasive outcome than destruction of
single lineages or differentiated cells that pre-
dominate in adults. This phenomenon is
exemplified in immunotoxicity studies with
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)
and diethylstilbestrol, where the immunologic
effects in the neonate are qualitatively and
quantitatively different than those that occur
in adult animals (Faith and Moore 1977;
Gehrs and Smialowicz 1999; Kalland 1982;
Luster et al. 1979; Ways et al. 1987).
Development of the Immune
System
Ontogenesis of the immune system in verte-
brates is well characterized and involves
sequential multiple switching of hematopoietic
compartments, resulting in highly regulated
cell production, cell migration into primary
and secondary lymphoid organs, and cell dif-
ferentiation within these organs under
microenvironmental influences. A detailed dis-
cussion of this topic is beyond the scope of this
document; the reader is referred to recent
reviews (Fadel and Sarzotti 2000; Marshall-
Clarke et al. 2000; Landreth 2002). For the
most part, the events involved in development
of the immune system are similar in humans
and species used in experimental studies,
including rodents. One major difference, how-
ever, is that in humans the immune system is
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well developed by the end of the first trimester
(13 weeks) of gestation, whereas in rodents
immune system ontogenesis continues
throughout gestation and into early postnatal
life, until the animal almost reaches sexual
maturity. Thus, the stage of immune develop-
ment at the time of birth, as well as the level of
immunocompetence during early postnatal
life, varies between species. For example,
hematopoiesis in rodents occurs primarily in
the fetal liver until several days after birth,
whereas in humans hematopoiesis begins to
diminish in the liver and predominate in the
bone marrow beginning in the fifth month of
gestation (Abboud and Lichtman 2001).
Although species-specific differences in matu-
rational times occur in other organ systems as
well (Stites et al. 1974), the work group indi-
cated that it is essential that a study design
accommodate these differences to allow for
extrapolating from animal studies to humans.
“Windows of vulnerability” have been
proposed to exist during specific periods of
immune ontogeny (Dietert et al. 2000). This
concept is based on presumptions derived
from established processes of immune system
development rather than actual data with
developmental immunotoxic agents. Figure 1
identifies five discrete windows of immune
maturation in rodents, based on known peri-
ods of highly active cell expansion or cell col-
onization of lymphoid organs. In rodents,
the period of susceptibility first begins during
the embryonic period, as blood-forming pre-
cursors are formed, and continues into post-
natal life. Although similar windows of
vulnerability exist in humans, the relative
times that these events occur are correspond-
ingly earlier. This phenomenon has been
demonstrated in developmental immunotoxi-
city studies with lead, where different effects
may be observed depending on the test
species and window of exposure. For exam-
ple, alterations in macrophage and T-cell
function occur in rodents given full gesta-
tional lead exposure (Faith et al. 1979).
However, rats exposed to lead during the first
half of embryonic development show persis-
tent changes only in macrophage function,
whereas exposure later in development results
in both macrophage and T-dependent func-
tional deficiencies (Bunn et al. 2001).
Chickens exposed to lead at early stages of
embryonic development produce lower levels
of inflammatory mediators with no effects on
T-cell function, but exposure during the lat-
ter stages of incubation significantly sup-
presses T-cell function (Lee et al. 2001). The
consensus from the work group regarding
these studies was that determining specific
windows of vulnerability for individual
agents would be beneficial for studying
mechanisms of action but would have limited
value for hazard identification, and any study
design tailored for hazard identification
should consider a more global approach.
Experimental Design and
Immunologic Assays
As reflected in the peer-reviewed literature,
there is no consensus on the most appropriate
experimental species, designs, or tests for exam-
ining developmental immunotoxicity. This
random study approach may affect not only
the quality of the study but also the ability to
use the data in assessing human risk. The com-
mittee felt that there was a critical need to
identify the most appropriate experimental
designs and test procedures for developmental
immunotoxicology testing currently available.
The first issue that was considered by the
work group was selection of an appropriate test
species. After humans, the species in which we
know the most about the immune system is
the mouse. However, given that considerable
information now exists on the immune system
in rats, the historical reproductive toxicologic
database available in the rat, and the low back-
ground incidence of malformations as well as
stress effects in the rats, there was a consensus
that the rat should be the species of choice for
developmental immunotoxicology testing. For
developmental immunotoxicology studies that
address mechanisms of action, rather than haz-
ard identification, the mouse may be the
species of choice because methods, reagents,
and animal models (e.g., transgenic mice) are
more readily found. Limited examples exist
where both mice and rat data are available for
the same agent, and in most cases both species
appear to respond in a similar manner.
However, there are several notable exceptions.
For example, changes in thymus weights were
reported to be a more sensitive indicator than
antibody responses after prenatal TCDD expo-
sure in rats, whereas the reverse was found in
mice (Gehrs et al. 1997). Concerning strain
selection, no consensus was reached. It was
noted that outbred rats are more representative
of the human population and are commonly
employed in reproductive studies, although
inbred strains would introduce less variability
in immune tests.
The next topic addressed by the work
group was exposure design. Specifically, the
committee was asked to identify a design that
would best accommodate hazard identifica-
tion for developmental immunotoxicology.
Discussions focused on the following issues:
the need to establish an exposure paradigm
that would accommodate differences in kinet-
ics of immune maturation that exist between
humans and the test species (i.e., rats);
whether to include all periods of potential
vulnerability during immune ontogenesis
(Figure 1); and the importance of discerning
agents that prevent immune components
from developing fully versus those that simply
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Table 1. Examples of developmental immunotoxicants in rodents and humans.
Agents Species References
TCDD/polychlorinated biphenyls Rodents and humans Vos and Moore (1974); Faith and Moore (1977); 
Luster et al. (1980); Fine et al. (1989); Holladay 
et al. (1991); Blaylock et al. (1992); Dewailly et 
al. (1993); Weisglas-Kuperus et al. (1995); Gehrs 
and Smialowicz (1999)
Benzo[a]pyrene Rodents Urso and Gengozian (1980)
Lead acetate Rodents Luster et al. (1978); Faith et al. (1979); Miller et 
al. (1998); Chen et al. (1999); Dietert et al. (2000)
Di-n-octyltin dichloride Rodents Smialowicz et al. (1988)
Tributlyltin oxide Rodents Smialowicz et al. (1989)
Hexachlorobenzene Rodents Vos et al. (1979); Barnett et al. (1987)
Drugs of abuse Rodents and humans Figliomeni and Turkall (1997); del Arco et al. 
(alcohol, cocaine) (2000)
Chlordane Rodents Spyker-Cranmer et al. (1982); Barnett et al.
(1985, 1990a, 1990b); Theus et al. (1992)
Diethylstilbestrol Rodents and humans Luster et al. (1979); Kalland (1982); Ways et al.
(1987)
JP-8 jet fuel Rodents Dudley et al. (2001); Ramos et al. (2002)
Figure 1. Relative time line of critical windows of exposure for immune system development in mice and
rats (adapted from Dietert et al. 2000). Abbreviations: GD, gestational day; PND, postnatal day.
GD 7–9 GD 9–16 GD 13–birth Birth–PND 30 PND 30–60















delay immune maturation. Also of concern to
the committee was identifying an exposure
design that would accommodate appropriate
times for measuring immune response after
antigen challenge, the hallmark of adaptive
immunity. Several examples were provided
that served to demonstrate the important
interrelationship between time of exposure,
time of measurement, and assay selection. In
human neonates, for example, not only are
immune responses weak but also there is
skewing of responses such that T-helper 2
(TH2), rather than TH1 immunity predomi-
nates. Therefore, neonatal stimulation with
antigens dependent on specific cell types or
mediators may not allow for an optimal
response to occur (Ridge et al. 1998), and
evaluation of these responses at too early a
time point could potentially mask chemical
effects on immune function. This can be
shown when hydrocortisone is administered
late in gestation in rodents, because inhibition
of the antibody response can be observed at
postnatal day (PND) 28 but not at PND 14
(Ezine and Papiernik 1981).
The major objective of the work group
was to identify a simple study design that
best addressed hazard identification, so it was
agreed that the exposure design should be
sufficiently flexible to be incorporated into
existing developmental toxicology protocols,
rather than needing to be a “stand-alone”
study. Existing study protocols, such as the
one-generation, two-generation, or segment
III studies (for pharmaceuticals) would be
suitable because they cover most, if not all, of
the critical periods for immune system devel-
opment. Stimulated by the National
Research Council report (1993), Pesticides in
the Diets of Infants and Children, a collabora-
tive research project was initiated between
the National Institute of Environmental
Health Sciences and the U.S. EPA to address
some of the scientific and regulatory concerns
in this area by exploring the long-term effects
of pesticide exposure on noncancer end
points in neonatal rats (Chapin et al. 1997;
Smialowicz et al. 2001). The experimental
design established by this group addressed
many of the concerns voiced by the work
group. Specifically, the design employed rats,
was well-suited for hazard identification,
could be incorporated into a preexisting
study design, covered all of “the windows of
vulnerability,” and could address possible
long-lasting effects. A schematic diagram of
the design that allows for immunotoxicology,
neurotoxicology, and reproductive and gen-
eral toxicology assessment is shown in Figure
2 (Smialowicz et al. 2001). In this protocol,
pregnant dams are dosed from gestational
day 12 to PND 7. On PND 8, the pups are
dosed directly using the same dose levels,
which continues until PND 42, the approxi-
mate end of puberty in rats and a time when
the immune system is fully mature. Litters
are standardized to four males and four
females on PND 7 and weaned on PND 21.
Subsets of rats (one male and one female
from each litter) are used for immunologic
evaluation on day 42. Other pups in the lit-
ter may be used for reproductive or lacta-
tional assessment and necropsy. The work
group emphasized the need to include, as a
minimum, plasma concentrations of the test
agent in order to help document placental or
breast milk transfer of the test material. If the
agent is transferred in breast milk, the
requirement of directly exposing the neonate
before weaning will need to be reconsidered.
Independent of the treatment route, exposure
through PND 42 is required to accommo-
date the entire period of immunologic onto-
genesis. Limitations in this study design are
that relatively few animals are examined, lim-
ited mechanistic information is provided,
and neither long-term effects nor recovery is
routinely assessed.
The next issue addressed by the work
group was determining the most appropriate
assays for identifying developmental immuno-
toxicants. Although perinatal exposure to
immunotoxic agents may have severe and
persistent effects on immune function, there is
no universal agreement on what constitutes the
most predictive or sensitive perinatal tests,
unlike studies with adults. Discussions focused
on the need to employ end points that accom-
modate the temporal nature of the matura-
tional processes, reflect the function and
interactions of the major cellular components
that constitute the immune system, and are
well understood biologically.
The National Toxicology Program has
conducted extensive studies in adult mice for
immunotoxicity using a “tiered” approach
(Luster et al. 1988). The database from these
studies, which covers more than 50 com-
pounds, has been collected and analyzed in an
attempt to improve the accuracy and effi-
ciency of screening chemicals for immuno-
suppression and to better identify those tests
that predict immune-mediated diseases
(Luster et al. 1992, 1993). Of the end points
examined, quantification of the T-dependent
antibody response was shown to be a highly
reliable indicator for immunotoxicity, as indi-
cated by its ability to identify immunotoxicity
and predict changes in host resistance. This
may be because the T-dependent antibody
response represents a specific response to anti-
gen and involves most of the major cell types
in the immune system (i.e., B cells, TH2 cells,
antigen-presenting cells) and mediators [i.e.,
tumor necrosis factor, interleukin-1 (IL-1),
IL-4, interferon γ, adhesion molecules].
Subsequent studies in other experimental
species, including rats (Temple et al. 1993),
have helped confirm these observations. The
clinical relevance of the antibody response,
(e.g., in relation to childhood vaccines and
resistance to certain bacterial pathogens) and
the opportunity to make direct comparisons
with humans were also considered advantages.
With this in mind, investigators have exam-
ined immune responses to childhood vaccines
to determine immunotoxicity in Dutch
preschool children exposed perinatally to
environmental polychlorinated biphenyls and
dioxins (Weisglas-Kuperus et al. 1995).
The committee’s recommendations for
an assay battery that fulfilled most of the cri-
teria set forth are listed in Table 2 and
include, among others, quantifying the pri-
mary antibody response to a T-dependent
antigen, although the committee did not
determine the optimal age at which the test
animal should be examined. It has previously
been established that the antibody response in
rats approximates a fully mature response by
PND 42, whereas at PND 21 the response
has yet to reach maximum levels (Ladics et al.
2000). The responses obtained between
PNDs 21 and 42 have yet to be closely exam-
ined, and kinetic studies will need to be con-
ducted between these time points to more
clearly identify when maximum antibody
titers are first obtained. The committee did
not provide recommendations for any spe-
cific antigen but discussed the benefits and
disadvantages of some commonly used anti-
gens, such as sheep red blood cells (RBCs)
and tetanus toxoid. If antibody tests were
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Figure 2. Schematic diagram of proposed experi-
mental design in rats that include immunotoxicology
testing (adapted from Chapin et al. 1997).














Table 2. Recommended developmental immunotoxicity assays.
Recommended screening assays Assays for validationa Assays for research development
Primary antibody response (T-dependent) Phenotypic analyses Stem cell assays
Delayed hypersensitivity response Macrophage function
CBC Natural killer cell activity
Thymus, spleen, and lymph node weights
aParticularly, validation of the correlation between the assay end point and functional outcomes in humans.
conducted using antigens commonly employed
in childhood vaccines, the results would be
more applicable to human studies. However,
there is no reason to believe that the response
to sheep RBCs would be any different from
those to other antigens, and reagents and
methods for using sheep RBCs are established
in rats. The committee also recommended
measurement of thymus, spleen, and lymph
node weights, although the latter two could
be influenced by immunization. Careful mea-
surement of thymus weights has provided
more consistent data than has thymus cellu-
larity and appears to be a consistent indicator
of developmental immunotoxicity (Holladay
and Luster 1996). There was broad consensus
that complete blood counts (CBCs) are also a
potentially useful and sensitive measure in
neonates. Intense hematopoietic development
occurs early in neonatal development, and
any moderate to major loss in a cell lineage
may be reflected as a decrease in the CBC or
altered differential. Lastly, the committee rec-
ommended, in addition to antibody response,
inclusion of a second functional test that
would provide a measure of TH1 immunity,
such as the cytotoxic T-lymphocyte assay or
the more commonly employed delayed hyper-
sensitivity response.
Several assays were discussed that are com-
monly employed in clinical immunologic eval-
uations and immunotoxicity testing in adults,
but their utility in developmental immunotox-
icity testing would require further evaluation.
These include macrophage function, comple-
ment analysis, and surface marker analysis
(Table 2). The opportunities and limitations
of cell surface marker analyses were given par-
ticular attention because they have been used
extensively to study immune development
and because animal studies have shown that
alterations in fetal thymus and fetal liver
hematopoietic cell numbers and phenotypes
are a common occurrence after gestational
exposure to developmental immunotoxic
agents. In particular, depression of fetal thy-
mus cell numbers and qualitative and quanti-
tative changes in surface marker expression on
precursors cells in the fetal liver and thymus
have been observed by cytometric analyses in
rodents after exposure to a variety of immuno-
toxic agents, including dioxins, diethylstilbe-
strol, ethylene glycol monomethylether,
benzo[a]pyrene, and T2 mycotoxin [reviewed
by Holladay and Luster (1996)]. The clinical
consequences of these changes have not been
established. However, if the effects are severe
enough, long-term immunosuppression,
anergy (i.e., failure to respond to antigen), or
autoimmunity may result by affecting posi-
tive and negative selection processes that
occur early in immune system development
(Hardin et al. 1992; Kamath et al. 1998;
Silverstone et al. 1994). Cytometric analysis
for both the frequency and the intensity of
common surface molecules (e.g., B220,
CD3, CD4, and CD8), as well as precursor
surface molecules (e.g., terminal deoxy-
nucleotidyl transferase, c-Kit, CD25, CD19,
CD43, CD69, and IL-7R), has often been
used to examine lymphoid tissues from pre-
nates and neonates. The work group recog-
nized that cytometric analyses may be highly
sensitive and can signal chemical-induced
effects on maturation and development.
However, concerns regarding its use as a
screening tool centered on the inability to
interpret the biologic significance of quanti-
tative changes in precursor and lineage-spe-
cific cell numbers. Therefore, its current use
may be more applicable to mechanistic stud-
ies (Immunotoxicology Technical Committee
2001).
A third group of tests, representing gen-
eral and lineage-specific stem cell assays
(Weissman et al. 2001), were considered to
have potential utility within the context of
early (i.e., prenatal) developmental immuno-
toxicology screening (Table 2). From a mech-
anistic standpoint, these tests have greatly
increased our understanding of hematopoi-
etic processes. Although these assays are
increasingly used in preclinical tests for phar-
maceuticals to help identify potential adverse
drug reactions of a hematologic nature
(Parent-Massin 2001), as yet they have
unknown utility in developmental immuno-
toxicology screening and will require further
investigation.
Summary
During the last 20 years, reproductive toxicol-
ogists and immunotoxicologists have identi-
fied a number of procedures and issues
relative to testing methods, study design, and
data interpretation for examining potential
developmental immunotoxicants. This work-
shop brought together experts with a wide
variety of backgrounds and areas of expertise.
Their discussions focused on establishing a
framework for the development of rational
testing guidelines as regulatory agencies grap-
ple with the issue of environmental exposures
and children’s health. Although consensus
was reached on most topics, in those that
were not, data gaps and research needs were
identified. The conclusions from the work-
shop described in this summary report are
meant to aid in conducting developmental
immunotoxicity studies and reduce some of
the uncertainties that exist in extrapolating
data from experimental animals to estimates
of risk in humans. Given the limited experi-
ence in screening for developmental immuno-
toxic agents, the listed test procedures should
be considered, at best, recommendations that,
as time proceeds and data accumulate, will
and should undergo revision.
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